A ‘wonky’ congressional report will be a pharma talking point in the drug pricing debate

September 20, 2021

As lawmakers in Washington grapple with legislation to alter the upward trajectory of prescription drug prices, a key talking point is likely to be found in a recent report from the Congressional Budget Office. Released late last month with little fanfare, the analysis concluded that limiting prices — as envisioned in a controversial House bill known as H.R. 3 — would lead to 59 fewer new drugs over the next three decades.

Read the source article at cancermenia.blogspot.com
2021-09-16 11:00:00

Share This Story!